Overview

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Status:
Completed

Trial end date:
2019-02-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).

Phase:

Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Treatments:

Axitinib